Newsroom
Sorted by: Latest
-
HSS Studies Contribute Early Evidence to Help Guide Emerging Perioperative Considerations for Patients Using GLP‑1 Medications
PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide-1 (GLP-1) agonist usage in patients undergoing surgery. GLP-1 agonists are a class of medications commonly prescribed to treat type 2 diabetes and obesity, and their therapeutic potential is extending to a range of conditions including cardiovascular and neurodegenerative...
-
Inocras and Broad Institute Researchers Present New TCGA Whole-Genome Cancer Insights, Accelerating Discovery in Cancer Genomics
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Researchers from Inocras, a bioinformatics-led company harnessing the power of whole-genome data and proprietary analytics to advance precision health, and the Broad Institute of MIT and Harvard will jointly present new insights from a collaborative initiative to analyze large-scale whole genome data during the AACR Annual Meeting 2026 in San Diego. The collaboration delivers one of the largest cancer whole-genome analyses from over 8,000 cancer wh...
-
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could h...
-
Rosen Law Firm Encourages Green Circle Decarbonize Technology Ltd. Investors to Inquire About Securities Class Action Investigation – GCDT
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Green Circle Decarbonize Technology Ltd. (NYSE American: GCDT) resulting from allegations that Green Circle may have issued materially misleading business information to the investing public. So what: If you purchased Green Circle securities you may be entitled to compensation without payment of any out of pocket fees or costs...
-
Baron & Budd Finalizes $774 Million Settlement With Albertsons in Nationwide Opioid Litigation
DALLAS--(BUSINESS WIRE)--This week, the nationally recognized law firm Baron & Budd announced the finalization of a $774 million nationwide settlement agreement with retail pharmacy giant Albertsons Companies, Inc. Albertsons has agreed to the payout which will be distributed to states, counties, municipalities, and Native American tribes to resolve allegations concerning the company’s role in the opioid epidemic. Baron & Budd’s President and Managing Shareholder, Russell Budd, played a...
-
ENPH Deadline: Rosen Law Firm Urges Enphase Energy, Inc. (NASDAQ: ENPH) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Enphase Energy, Inc. (NASDAQ: ENPH) between April 22, 2025 and October 28, 2025, inclusive (the “Class Period”). Enphase is a energy technology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Enphase En...
-
HSS Presents New Research Leveraging AI to Uncover Insights Related to Pain Risk and Anesthesia Education at ASRA Annual Meeting
PHOENIX--(BUSINESS WIRE)--At this year’s American Society of Regional Anesthesia and Acute Pain Medicine (ASRA) annual meeting, investigators at Hospital for Special Surgery (HSS) presented significant studies leveraging artificial intelligence (AI) to provide insights into long-term pain risk after surgery and what patients want to know about anesthesia. These insights may ultimately help guide anesthesiologists’ consultations with patients scheduled for surgery. What follows are highlights fr...
-
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class t...
-
Deep Fission to Host Community Webinar on Advanced Nuclear Project in Parsons, Kansas
PARSONS, Kan.--(BUSINESS WIRE)--Deep Fission, Inc. (“Deep Fission” or the “Company”), will host a community engagement webinar on Tuesday, April 21, at 7 p.m. CDT, inviting the public to learn more about the company’s advanced nuclear energy project in Parsons, Kansas. The webinar will feature Deep Fission Chief Operating Officer Mike Brasel, who will provide an overview of the company’s technology, project plans, and ongoing community efforts. Attendees will have the opportunity to submit ques...
-
The First Chinese Flagship to Truly Challenge BBA High-Performance SUV Has Arrived
NINGBO, China--(BUSINESS WIRE)--Zeekr, a global luxury technology brand under Geely Auto Group, officially launched the Zeekr 8X, an all-new high-performance flagship SUV. The new model further enhances the brand’s luxury SUV portfolio by forming a dual-flagship lineup with the Zeekr 9X. Industry observers believe this is the first Chinese flagship capable of posing a genuine threat to the long-standing dominance of BBA brands—BMW, Mercedes-Benz, and Audi—in the global high-performance SUV segm...